DexCom Faces Class Action Lawsuit Over Securities Violations

2025-11-11 companies

New York, Monday, 10 November 2025.
DexCom, Inc. is embroiled in a class action lawsuit alleging securities law violations due to unauthorized design changes in its G6 and G7 devices. Investors have until December 26, 2025, to join.

Allegations and Class Period

The class action lawsuit against DexCom, Inc. (NASDAQ: DXCM), filed on November 9, 2025, alleges that the company made unauthorized design changes to its G6 and G7 glucose monitoring devices, which were not approved by the U.S. Food and Drug Administration (FDA). These changes reportedly compromised the devices’ reliability and posed health risks to users, leading to financial losses for investors [1][2][4]. The class period for the lawsuit spans from July 26, 2024, to September 17, 2025, during which the alleged violations occurred [1][2][5].

Legal Representation and Deadlines

The class action is being pursued by multiple law firms, including The Gross Law Firm, Lowey Dannenberg P.C., and Levi & Korsinsky, LLP, all of which are recognized for their expertise in securities litigation [1][2][5]. Investors who have suffered significant losses, particularly those exceeding $100,000, are encouraged to join the lawsuit [5]. The deadline for investors to apply for lead plaintiff status is December 26, 2025 [1][2][5].

Impact on Investor Confidence

This lawsuit comes amid increasing scrutiny of corporate governance and financial reporting practices, particularly in the healthcare sector. DexCom’s stock has been under pressure following these allegations, as investors reevaluate the company’s compliance with regulatory standards and its impact on financial performance [1][5][6]. The outcome of this lawsuit could have significant implications for DexCom’s reputation and investor confidence moving forward [5][6].

Market Reaction and Future Prospects

The news of the lawsuit has triggered a wave of concern among shareholders, prompting them to seek legal counsel to potentially recover their losses [1][5]. As the December 26 deadline approaches, it is crucial for investors to understand their rights and the potential outcomes of this legal action. The resolution of this case will likely influence DexCom’s future market position and its ability to navigate regulatory challenges [1][5][6].

Sources

securities law DexCom class action